This week we've had Eyes On Commercial Development and the FDA. Several companies have announced partnerships / acquisitions to further boost their pipelines and strengthen their competitive advantage.

Lately, we've kept our Eyes On Sarepta Therapeutics and their discussions with the US FDA regarding their gene therapy Product Elevidys, their pipeline platform. All of this, plus the management shuffles at the FDA itself, has created quite a stir in the industry.

 This month we've had Eyes On The BBB and potential timing and impact on the BioPharma sector. This is a dynamic area, with many different news bytes daily, let us know what you'v e seen and what sources you are following.

We're catching up on the latest news and views surrounding the BioPharma Industry & Tariffs.

We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

Here at PharmaTell, we have Eyes on FDA Approvals for 2025. Below, we share the monthly Novel Drug and Biologic License Application Approval

Check out the final listings of FDA NDA and BLA approvals for 2024.

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

This week we've had eyes on BioPharma happenings plus a 2023 Top Selling Drugs list.

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.

This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01

This week, the team has been looking at congress planners, earnings call transcripts, and the US FDA.

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.